Kymera (KYMR) to Raise $225 Million Through Offering of Shares [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
The company is selling approximately 2 million shares of common stock at a public offering price of $40.75 per share. In addition, it is selling pre-funded warrants to purchase 3.5 million shares in the offering in lieu of common stock to certain investors. The pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant. This offering price represents the per share public offering price of each share of common stock minus the exercise price of $0.0001 per share for each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $225 million, which will be used by Kymera to advance its pipeline of preclinical and clinical degrader programs. It will also be utilized for working capital and other general corporate purposes. Kymera may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or technologies to continue to build its pipeline, research and development capabili
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock.MarketBeat
- Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswire
- Kymera upgraded, MoonLake downgraded: Wall Street's top analyst calls [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 8/7/24 - Beat
KYMR
Sec Filings
- 9/17/24 - Form 4
- 9/17/24 - Form 144
- 8/26/24 - Form 4
- KYMR's page on the SEC website